Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA1B | Q00975 | 5/20 | 0.37 |
| ▸ | BCL2 | P10415 | 5/20 | 0.35 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.35 |
| ▸ | GSTP1 | P09211 | 1/20 | 0.34 |
| ▸ | GSTM2 | P28161 | 1/20 | 0.34 |
| ▸ | PPARG | P37231 | 1/20 | 0.33 |
| ▸ | PPARA | Q07869 | 1/20 | 0.33 |
| ▸ | SYK | P43405 | 1/20 | 0.33 |
| ▸ | ATM | Q13315 | 1/20 | 0.32 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.31 |
| ▸ | TACR1 | P25103 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28907023 | 1.00 | CACNA1B (0.37) | CACNA1BBCL2MCL1GSTP1GSTM2 | |
| SCHEMBL16974997 | 0.93 | BCL2 (0.37) | CACNA1BBCL2MCL1GSTP1GSTM2 | |
| SCHEMBL16974998 | 0.93 | BCL2 (0.37) | CACNA1BBCL2MCL1GSTP1GSTM2 | |
| SCHEMBL18428044 | 0.93 | BCL2 (0.37) | CACNA1BBCL2MCL1GSTP1GSTM2 | |
| SCHEMBL18428045 | 0.93 | BCL2 (0.37) | CACNA1BBCL2MCL1GSTP1GSTM2 | |
| SCHEMBL23877847 | 0.93 | BCL2 (0.37) | CACNA1BBCL2MCL1GSTP1GSTM2 | |
| SCHEMBL28518881 | 0.88 | BCL2 (0.36) | CACNA1BBCL2MCL1GSTP1GSTM2 | |
| SCHEMBL16979723 | 0.87 | — | — | |
| SCHEMBL18472331 | 0.87 | — | — | |
| SCHEMBL16970781 | 0.85 | BCL2 (0.36) | CACNA1BBCL2MCL1GSTP1GSTM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9394237-B2 | β-substituted β-amino acids and analogs as chemotherapeutic agents | QUADRIGA BIOSCIENCES, INC. (US) | 2016-07-19 | — | — | US | disclosed |
| US-20150218086-A1 | BETA-SUBSTITUTED BETA-AMINO ACIDS AND ANALOGS AS CHEMOTHERAPEUTIC AGENTS | QUADRIGA BIOSCIENCES, INC. | 2015-08-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150218086-A1 | BETA-SUBSTITUTED BETA-AMINO ACIDS AND ANALOGS AS CHEMOTHERAPEUTIC AGENTS | SLC7A1, SLC3A2, SLC1A5 | CACNA1B 2354/4885BCL2 1635/4885MCL1 216/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.